Get the Stockscreener App
2.59
1.89%
-0.05
After Hours:
2.60
0.01
+0.39%
Aytu Biopharma Inc stock is traded at $2.59, with a volume of 39,753.
It is down -1.89% in the last 24 hours and up +19.35% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.64
Open:
$2.65
24h Volume:
39,753
Relative Volume:
0.43
Market Cap:
$27.80M
Revenue:
$62.64M
Net Income/Loss:
$-24.56M
P/E Ratio:
-0.6747
EPS:
-3.8387
Net Cash Flow:
$-3.70M
1W Performance:
-0.38%
1M Performance:
+19.35%
6M Performance:
+11.64%
1Y Performance:
+110.57%
1-Day Range:
$2.58
$2.685
1-Week Range:
$2.49
$2.70
52-Week Range:
$0.95
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.59 | 28.34M | 62.64M | -24.56M | -3.70M | -3.8387 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.39 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
121.68 | 49.87B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.60 | 46.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.09 | 34.31B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
540.02 | 23.42B | 3.18B | 1.33B | 1.04B | 27.90 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
History Review: What hedge funds are buying Aytu BioPharma Inc2026 Price Momentum & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Aytu BioPharma : Corporate Presentation March 2026 View Presentation Investor Day January 2026 View Presentation - marketscreener.com
Bull Run: Will Aytu BioPharma Inc benefit from rising consumer demand2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Aytu BioPharma, Inc. (AYTU) Competitors - Meyka
Will Aytu BioPharma Inc. stock deliver consistent dividendsJuly 2025 Levels & Consistent Growth Stock Picks - Naître et grandir
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
AYTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aytu BioPharma AYTU Q2 2026 Earnings Transcript - AOL.com
Is Aytu BioPharma Inc. forming a double bottomGlobal Markets & Intraday High Probability Alerts - mfd.ru
Is Aytu BioPharma Inc. stock a good pick for beginnersJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - mfd.ru
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lytton, foundation report 9.99% Aytu BioPharma (AYTU) stake - Stock Titan
What is the cash position of Aytu BioPharma Inc.2025 Trading Recap & AI Forecasted Entry and Exit Points - mfd.ru
Panic Selling: What analysts say about Aytu BioPharma Inc stockMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
Breakouts Watch: What analysts say about Aytu BioPharma Inc stockMarket Risk Summary & High Accuracy Investment Signals - baoquankhu1.vn
Pharma News: Is Aytu BioPharma Inc. (AY20) stock testing key support2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
Will Aytu BioPharma Inc. (AY20) stock benefit from infrastructure billRisk Management & Consistent Growth Stock Picks - mfd.ru
Is Aytu BioPharma Inc. a strong candidate for buy and hold2025 Macro Impact & Short-Term High Return Ideas - mfd.ru
How Aytu BioPharma Inc. (AY20) stock gains from tech spendingGlobal Markets & Advanced Technical Analysis Signals - mfd.ru
Will Aytu BioPharma Inc. outperform tech stocksShare Buyback & Smart Allocation Stock Tips - mfd.ru
Will Aytu BioPharma Inc. benefit from rising consumer demandJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - mfd.ru
Lake Street Remains a Buy on Aytu BioScience (AYTU) - The Globe and Mail
Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance
Aytu BioPharma Q2 Earnings Call Highlights - Defense World
Full Transcript: Aytu BioPharma Q2 2026 Earnings Call - Benzinga
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navi - GuruFocus
Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com Nigeria
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill
AYTU: Exxua launch drives early momentum; net revenue $15.2M, net loss $10.6M on launch costs - TradingView
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
AYTU Reports Q2 Revenue Decline Amid Shift to New Product Launch - GuruFocus
Aytu BioPharma Q2 Earnings Summary & Key Takeaways - Benzinga
Aytu BioPharma Q2 Earnings Assessment - Benzinga
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Res - GuruFocus
New Strong Sell Stocks for February 2nd - Nasdaq
Earnings Recap: Is Aytu BioPharma Inc stock influenced by commodity pricesProduct Launch & Weekly Market Pulse Alerts - baoquankhu1.vn
Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire
Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
New EXXUA depression drug targets MDD without sexual side effects - Stock Titan
AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView
AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView
Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):